Dante/
ç·æ§/
ï¼ï¼ä»£/
大åç
The United States http://12yo.icu 14yo Morphosys and Xencor said their phase 1/2a clinical trialevaluating MOR208 in patients with relapsed or refractorychronic lymphocytic leukemia showed an overall response rate of29.6 percent, up from 14.8 percent previously.
2019-05-23 09:20:59 / Comment:(0) 返信